Sub: Outcome of the Meeting of the Board of Directors held on August 07, 2026. This has reference to our letter dated 22nd July 2026, Intimating the meeting of the Board of Directors of ....

Date:07-08- 2026 The General Manager Department of Corporate Services, BSE Ltd., Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001 Scrip Code: 526139 Dear Sir / Madam, Sub: Outcome of the Meeting of the Board of Directors held on August 07, 2026. This has reference to our letter dated 22nd July 2026, Intimating the meeting of the Board of Directors of the Company. At a meeting of the Board of Directors of the company held on 07th August 2026 the following decisions have been taken: 1) The Board considered and approved the Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter ended 30thJune 2026. 2) The Board considered and approved the Limited Review Report (Standalone & Consolidated) of the Company for the quarter ended 30thJune 2026. 3) The Board considered and approved the extension of the date of Annual General Meeting (AGM) of the Company for the financial year 2025-26, subject to obtaining the necessary approval from the Registrar of Companies, wherever applicable. 4) The Board considered and approved the appointment of M/s. Manisha Dubey & Associates, as Internal Auditors of the Company for the financial year 2026-27. The meeting of the Board of Directors commenced at 11:00 A.M. and concluded at 11:30 Thanking you Yours Sincerely For TRANSGENE BIOTEK LIMITED DR. K. KOTESWARA RAO CHAIRMAN & MANAGING DIRECTOR Encls: as above Plot 69 &70 , IDA Bollaram, SangareddyDistrict–502 325, Telangana, India Ph: +91-40-65589499 Fax: +91-8458-279755 Web:www.transgenebiotek.com Email:info@transgenebiotek.com, CIN No: L85195AP1990PLC011065 Disclosure pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015 read with SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024. Sr.No Particulars Internal Auditors 1 Name of Auditors M/s. Manisha Dubey & Associates, Chartered Accountants (Proprietor: Ms. Manisha Dubey), Internal Auditors 2 Reason for change: Appointment Appointment of M/s. Manisha Dubey& Associates, a Peer Reviewed Firm of Chartered Accountant in Practice, having Membership No.212664, as Internal Auditor of the Company. 3 Date of appointment and term of The Board at its meeting held on August 07, 2026, appointment approved the appointment of M/s. Manisha Dubey & Associates, Chartered Accountant, as Internal Auditors of the Company for the financial year 2026-27. 4 Brief profile (in case of Ms. Manisha Dubey, Sole Proprietor firm of Chartered appointment) Accountant. Ms. Manisha Dubey has more than 24 years “M/s Manisha Dubey & Associates”, is a Chartered Accountants firm having extensive experience in internal audit and Internal Financial Controls reviews. 5 Disclosure of relationships Not applicable between directors (in case of appointment) Plot 69 &70 , IDA Bollaram, Sangareddy District–502 325, Telangana, India Ph: +91-40-65589499 Fax: +91-8458-279755 Web:www.transgenebiotek.com Email:info@transgenebiotek.com, CIN No: L85195AP1990PLC011065 TRANSGENE BIOTEK LIMITED Plot No:69 & 70, IDA Bollaram, Sangareddy District. IDA Bollaram Hyderabad TG 502325 IN CIN NO: L85195TG1990PLC011065 STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2026 (In Lakhs) Year to date Year to date figures for figures Quarter Ended Year Ended Sr. current period Previous year Particulars No. ended ended 30-06-2026 31-03-2026 30-06-2025 30-06-2026 30-06-2025 31.03.2026 (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) 1 Revenue from operations 6.00 5.45 4.95 6.00 4.95 21.12 2 Other income (net) 0.00 14.99 0.00 0.00 0.00 14.99 3 Total income (1 + 2) 6.00 20.43 4.95 6.00 4.95 36.11 4 EXPENSES Cost of materials consumed 0.00 0.00 0.00 0.00 0.00 0.00 Changes in inventories of finished goods, work-in-progress and Stock-in-trade 0.00 0.00 0.00 0.00 0.00 0.00 Employee benefits expense 3.37 3.38 4.72 3.37 4.72 14.73 Finance costs 28.95 27.68 24.55 28.95 24.55 106.02 Depreciation and amortisation expense 4.13 4.98 4.98 4.13 4.98 19.91 Other expenses 8.45 30.09 14.07 8.45 14.07 60.74 Total expenses 44.90 66.13 48.32 44.90 48.32 201.40 Profit before exceptional items, share of 5 profit from associate & joint venture and tax (3 - 4) -38.90 -45.70 -43.37 -38.90 -43.37 -165.29 6 Exceptional item (net) 0.00 0.00 0.00 0.00 0.00 0.00 7 Profit before tax (5 - 6) -38.90 -45.70 -43.37 -38.90 -43.37 -165.29 8 Tax expense Tax adjustments for earlier years 0.00 0.00 0.00 0.00 0.00 0.00 Current tax 0.00 0.00 0.00 0.00 0.00 0.00 Deferred tax 0.00 0.00 0.00 0.00 0.00 0.00 Total tax expense 0.00 0.00 0.00 0.00 0.00 0.00 9 Profit for the year (7 - 8) -38.90 -45.70 -43.37 -38.90 -43.37 -165.29 10 Other comprehensive income A Items that will not be reclassified subsequently to profit or loss (a) Remeasurements cost of post 0.00 0.00 0.00 0.00 0.00 0.00 employment benefits Total other comprehensive income 0.00 0.00 0.00 0.00 0.00 0.00 11 Total comprehensive income for the year (9 + 10) -38.90 -45.70 -43.37 -38.90 -43.37 -165.29 12 Earnings per equity share (Equity shares, par value of Rs. 10 each) 757.70 757.70 757.70 757.70 757.70 757.70 Basic (Rs.) (0.05) (0.06) (0.06) (0.05) (0.06) (0.22) Diluted (Rs.) (0.05) (0.06) (0.06) (0.05) (0.06) (0.22) Notes: 1 SECURITIES APPELLATE TRIBUNAL (SAT): The matter has been adjourned from 14th July 2026 to 17th August 2026. 2 APPELLATE TRIBUNAL (ED), NEW DELHI: The process of hearing against the order passed by ED Adjudication Officer has started and heard our side of argument on 23rd July 2026 and adjourned further to 10th September 2026. 3 SBIRI / BIRAC: There has been no further communication from BIRAC subsequent to the last board meeting on 14th November 2025. 4 NITIN DIDWANIA: The order in this matter was passed on 8th July asking an amount of Rs.92,99,250/- to be paid with an interest of 6% per annum on the principal amount of originally taken loan of Rs.25 lacs. Aggrieved by this order, we have filed an appeal at the Hon’ble High Court of Bombay Commercial Division. 5 CUSTOMS & EXCISE DEPARTMENT: There has been no further development on this matter since the last board meeting 6 NCLT: Our matter came up for hearing on 8th July 2026 and adjourned to 23rd September 2026. 7 COMPLAINTS: No. of complaints pending at the beginning of the quarter – 0; received complaints during the quarter – 0 8 AUDIT REVIEW: The auditors have carried out a limited review of the financial results for the quarter ended 30th June 2026 and following the approval by the audit committee, it has been passed by the Board of Directors at the meeting held on 7th August 2026 For TRANSGENE BIOTEK LIMITED Dr.K.Koteswara Rao Managing Director Date: 07/08/2026 Place:Hyderabad TRANSGENE BIOTEK LIMITED Notes forming part of the Standalone financial statements Other expenses (In Lakhs) For the Period ended Particulars on 30th June 2026 Advertisement 0.13 BSE Listing & Annual Custody fee 4.93 Bank charges 0.00 BSNL Fiber net 0.02 Directors sitting fee 0.15 Legal and Professional Charges 2.98 Office Expenses 0.17 Rates, taxes and duties 0.05 Repairs and maintenance 0.02 Telephone Expenses 0.02 Transport charges 0.00 Total 8.45 For TRANSGENE BIOTEK LIMITED Dr.K.Koteswara Rao Managing Director Date: 07/08/2026 Place:Hyderabad TRANSGENE BIOTEK LIMITED Plot No:69 & 70, IDA Bollaram, Sangareddy District. IDA Bollaram Hyderabad TG 502325 IN CIN NO: L85195TG1990PLC011065 STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2026 (In Lakhs) Year to date Year to date figures for figures Quarter Ended Year Ended Sr. current period Previous year Particulars No. ended ended 30-06-2026 31-03-2026 30-06-2025 30-06-2026 30-06-2025 31.03.2026 (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) 1 Revenue from operations 6.00 5.45 4.95 6.00 4.95 21.12 2 Other income (net) 0.00 14.99 0.00 0.00 0.00 14.99 3 Total income (1 + 2) 6.00 20.43 4.95 6.00 4.95 36.11 4 EXPENSES Cost of materials consumed 0.00 0.00 0.00 0.00 0.00 0.00 Changes in inventories of finis [Showing first 8,000 characters — download PDF for full document]